• SMPD4, Ceramide, and Primary Cilia in Brain Development

  2026-09-03

  The 2024 Development study establishes SMPD4-dependent ceramide production as a mechanistic link between sphingolipid metabolism, primary cilium maintenance, neural progenitor survival, and cerebellar development. By combining a mouse model with SMPD4-deficient human iPSCs and a ceramide-rescue experiment, the work moves beyond genetic association toward a cross-species disease mechanism for microcephaly and cerebellar hypoplasia.

• Glioblastoma Apoptotic Priming and BH3-Mimetic Targeting

  2026-09-03

  Koessinger and colleagues show that glioblastoma, including patient-derived stem-like cells, depends on elevated anti-apoptotic BCL-xL and MCL-1 activity and is therefore unusually susceptible to BH3-mimetic treatment. The study’s central translational insight is that sequential BCL-xL and MCL-1 inhibition can produce robust antitumor responses in vivo, providing a mechanistic framework for targeting treatment-resistant glioblastoma.

• CARMIL Membrane Binding Directs Actin Assembly

  2026-09-02

  Mooren and colleagues show that the CARMIL membrane-binding domain does more than localize capping protein (CP) to membranes: it also controls CP activation, release, and actin assembly. Their biochemical model explains how membrane-associated CARMIL can promote Arp2/3-dependent filament formation while allowing activated CP to function away from the membrane.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Guide

  2026-09-02

  Cy3 Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1209) provides fluorescent detection of rabbit IgG primary antibodies in immunofluorescence, IHC, ICC, and flow cytometry workflows. It is for research use only; product-specific dilution, incubation, tissue validation, and diagnostic performance are not established in the supplied dossier.

• Melanoma Apoptosis After Chloroquine and Everolimus

  2026-09-01

  The reference study shows that combining chloroquine with the mTOR inhibitor everolimus reduces melanoma-cell proliferation and activates apoptosis, while also producing measurable redistribution of intracellular lipid structures. Its integrated use of caspase, DNA-fragmentation, morphology, and lipid-imaging readouts provides a useful framework for interpreting cell-death responses beyond a single viability endpoint.

• Catalpol Workflow for Ischemic Stroke Research

  2026-09-01

  Build a mechanism-led Catalpol workflow around the neurovascular unit rather than measuring neuronal survival alone. This guide connects dose selection, 3D validation, pathway readouts, and troubleshooting for reproducible ischemic stroke experiments.

• SB 431542: Practical ALK5 Inhibitor Workflows

  2026-08-31

  Use SB 431542 to dissect TGF-β–dependent Smad2 signaling, glioma proliferation, immune modulation, and stem-cell lineage behavior with a workflow built around matched vehicle controls and orthogonal readouts. Its value is greatest when pathway suppression is separated from cytotoxicity and when ALK4/7 cross-reactivity is treated as an experimental variable.

• SIS3: Reading Smad3 in Complex TGF-β Networks

  2026-08-31

  SIS3 is a selective Smad3 inhibitor for dissecting how TGF-β signals become context-specific transcriptional and fibrotic phenotypes. This article connects enhancer biology, microenvironmental signaling, and layered assay design to improve mechanistic interpretation in oncology and fibrosis research.

• Morning Training Improves Endurance Adaptation in Mice

  2026-08-30

  Hesketh et al. show that endurance training during the early active phase produces faster and more efficient performance adaptation than training during the late active phase in female mice. The study separates acute time-of-day differences in capacity from the longer-term training response and identifies skeletal-muscle metabolic and contractile changes associated with early-active-phase training.

• Nanoparticle Uptake by Human Corneal Cells

  2026-08-29

  This 2024 study shows how PLGA nanoparticle size and surface chemistry shape uptake by human corneal epithelial cells. Using a mucosa-integrated in vitro model and inhibitor studies, the authors identify energy-dependent uptake dominated by macropinocytosis and caveolae-mediated endocytosis, providing formulation guidance for topical ocular delivery.

• PNU 74654: A Mechanism-First Wnt Inhibitor Guide

  2026-08-28

  PNU 74654 is a Wnt signaling pathway inhibitor for dissecting pathway activity, cell fate, and assay interpretation. This mechanism-first guide connects product handling with findings from skeletal muscle progenitor research while clarifying what the compound can—and cannot—demonstrate experimentally.

• EdU Imaging Kits (488) for Disease-Model Assays

  2026-08-28

  EdU Imaging Kits (488) provide a precise way to measure DNA synthesis while preserving cellular architecture. This article explains how to apply EdU imaging to distinguish reduced proliferation from senescence-associated phenotypes in preeclampsia-derived stem cells.

• Adult Stem Cell Protocols: Innovation and Translation

  2026-08-27

  Adult Stem Cells Methods and Protocols, Second Edition presents a reproducibility-centered framework for isolating, characterizing, culturing, and applying adult stem cells in regenerative research. Its main innovation is the integration of stepwise laboratory protocols with troubleshooting guidance and translational considerations, helping researchers connect cell preparation with tissue-engineering and therapeutic objectives.

• Cyclic Pifithrin-α Hydrobromide: Assay Logic

  2026-08-27

  Cyclic Pifithrin-α hydrobromide is a p53 inhibitor for dissecting transcription-dependent apoptosis and DNA damage responses. This guide focuses on causal assay design, controls, and the limits of translating p53 perturbation into neuroinflammation research.

• Measuring Drug Responses Beyond Cell Viability

  2026-08-26

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly interchangeable metrics capture different relationships between growth inhibition and cell death. The framework supports more rigorous cancer drug evaluation by separating cytostatic effects, cytotoxicity, and response timing rather than treating a single endpoint as a complete pharmacologic description.

8431 records 1/563 page Next 12345 下5页 Last page